Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Lauroxil for Preventing Psychotic Relapse in Schizophrenia
NCT04203056Phase 4Terminated
- Sponsor
- University of California, Los Angeles
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole lauroxil in schizophrenia, schizoaffective disorder and schizophreniform disorder (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: Exacerbation or Relapse of Psychotic Symptoms at 12 months. Started Dec 2019; status: terminated.
02
Drugs
aripiprazole lauroxil
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT04203056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203056.